Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Investigating the efficacy and safety of ADCT-602 in patients with R/R B-ALL

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from an ongoing Phase I/II trial evaluating ADCT-602, a CD22 targeting antibody-drug conjugate (ADC) bound to the pyrrolobenzodiazepine (PBD) toxin, in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) (NCT03698552). Overall, ADCT-602 appears to be efficacious, with patients showing evidence of clinical activity and achieving measurable residual disease (MRD)-negative remission. The safety profile of ADCT-602 is also encouraging, with no significant toxicities observed so far. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Aprea Therapeutics: Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel Support, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel Support, Research Funding; TransThera Sciences: Research Funding; Fate Therapeutics: Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Ipsen: Honoraria; Loxo Oncology: Research Funding; Medisix: Research Funding; Takeda: Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel Support, Research Funding; Servier Pharmaceuticals LLC: Research Funding; ADC Therapeutics: Research Funding; BMS: Consultancy, Honoraria, Other: Travel Support, Research Funding; Pfizer: Research Funding; Incyte Corporation: Research Funding; Cellectis: Honoraria, Research Funding; Dialectic Therapeutics: Research Funding; Novalgen: Research Funding; Newave: Research Funding; MEI Pharma: Honoraria; TG Therapeutics: Honoraria; Beigene: Honoraria; Cellectis: Honoraria, Research Funding; Mingsight: Research Funding; Pharmacyclics, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; Janssen Pharmaceuticals, Inc.: Consultancy, Honoraria, Other: Travel Support; Genentech, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel Support, Research Funding; CareDx: Honoraria.